Srihari S Naidu

List of Publications by Citations

93 papers	4,862 citations	27 h-index	69 g-index
110 ext. papers	6,082 ext. citations	3.5 avg, IF	5.15 L-index

#	Paper	IF	Citations
93	2011 ACCF/AHA Guideline for the Diagnosis and Treatment of Hypertrophic Cardiomyopathy: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Developed in collaboration with the American Association for Thoracic	15.1	792
92	2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. *Circulation*, **2011**, 124, 2761-96	16.7	587
91	2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. *Circulation*, **2011**, 124, e783-831	16.7	569
90	2015 SCAI/ACC/HFSA/STS Clinical Expert Consensus Statement on the Use of Percutaneous Mechanical Circulatory Support Devices in Cardiovascular Care: Endorsed by the American Heart Assocation, the Cardiological Society of India, and Sociedad Latino Americana de Cardiologia	15.1	320
89	SCAI clinical expert consensus statement on the classification of cardiogenic shock: This document was endorsed by the American College of Cardiology (ACC), the American Heart Association (AHA), the Society of Critical Care Medicine (SCCM), and the Society of Thoracic Surgeons (STS) in April	2.7	236
88	The current use of Impella 2.5 in acute myocardial infarction complicated by cardiogenic shock: results from the USpella Registry. *Journal of Interventional Cardiology*, **2014**, 27, 1-11	1.8	230
87	2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. *Journal of Thoracic and Cardiovascular Surgery*, **2011**, 142, e153-203	1.5	212
86	2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. *Journal of the American College of Cardiology*, **2011**, 58, 2703-38	15.1	194
85	Cardiogenic Shock Classification to Predict Mortality in the Cardiac Intensive Care Unit. *Journal of the American College of Cardiology*, **2019**, 74, 2117-2128	15.1	149
84	Hospital Volume Outcomes After Septal Myectomy and Alcohol Septal Ablation for Treatment of Obstructive Hypertrophic Cardiomyopathy: US Nationwide Inpatient Database, 2003-2011. *JAMA Cardiology*, **2016**, 1, 324-32	16.2	135
83	Real-world use of the Impella 2.5 circulatory support system in complex high-risk percutaneous coronary intervention: the USpella Registry. *Catheterization and Cardiovascular Interventions*, **2012**, 80, 717-25	2.7	109
82	Novel percutaneous cardiac assist devices: the science of and indications for hemodynamic support. *Circulation*, **2011**, 123, 533-43	16.7	96
81	Renal insufficiency is an independent predictor of mortality after percutaneous coronary intervention. *American Journal of Cardiology*, **2003**, 92, 1160-4	3	95
80	2015 SCAI/ACC/HFSA/STS Clinical Expert Consensus Statement on the Use of Percutaneous Mechanical Circulatory Support Devices in Cardiovascular Care (Endorsed by the American Heart Association, the Cardiological Society of India, and Sociedad Latino Americana de Cardiologia	3.3	86
79	Contemporary incidence and predictors of stent thrombosis and other major adverse cardiac events in the year after XIENCE V implantation: results from the 8,061-patient XIENCE V United States study. *JACC: Cardiovascular Interventions*, **2012**, 5, 626-35	5	72
78	2014 ACC/AHA/AATS/PCNA/SCAI/STS focused update of the guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines, and the American	1.5	71
77	Considerations for cardiac catheterization laboratory procedures during the COVID-19 pandemic perspectives from the Society for Cardiovascular Angiography and Interventions Emerging Leader Mentorship (SCAI ELM) Members and Graduates. *Catheterization and Cardiovascular Interventions*,	2.7	69

76	The science behind percutaneous hemodynamic support: a review and comparison of support strategies. *Catheterization and Cardiovascular Interventions*, **2012**, 80, 816-29	2.7	67
75	COVID-19 Pandemic: Cardiovascular Complications and Future Implications. *American Journal of Cardiovascular Drugs*, **2020**, 20, 311-324	4	63
74	2015 SCAI/ACC/HFSA/STS Clinical Expert Consensus Statement on the Use of Percutaneous Mechanical Circulatory Support Devices in Cardiovascular Care: Endorsed by the American Heart Association, the Cardiological Society of India, and Sociedad Latino Americana de Cardiologia Intervencionista; Affirmation of Value by the Canadian Association of Interventional Cardiology-Association Canadienne de Cardiologie d'Intervention. *Journal of the American College of Cardiology*, **2015**, 65, 2140-1	15.1	59
73	2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. *Journal of Thoracic and Cardiovascular Surgery*, **2011**,	1.5	59
72	SCAI expert consensus statement: 2016 best practices in the cardiac catheterization laboratory: (Endorsed by the cardiological society of india, and sociedad Latino Americana de Cardiologia intervencionista; Affirmation of value by the Canadian Association of interventional cardiology-Association canadienne de cardiologie d'intervention). *Catheterization and Cardiovascular Interventions*, **2016**, 88, 407-23	2.7	48
71	Clinical expert consensus statement on best practices in the cardiac catheterization laboratory: Society for Cardiovascular Angiography and Interventions. *Catheterization and Cardiovascular Interventions*, **2012**, 80, 456-64	2.7	44
70	Impact of severity of renal dysfunction on determinants of in-hospital mortality among patients undergoing percutaneous coronary intervention. *Catheterization and Cardiovascular Interventions*, **2012**, 80, 352-7	2.7	43
69	Transcatheter device closure of interatrial septal defects in patients with hypoxia. *Journal of Interventional Cardiology*, **2005**, 18, 227-32	1.8	36
68	The State of the Absorb Bioresorbable Scaffold: Consensus From an Expert Panel. *JACC: Cardiovascular Interventions*, **2017**, 10, 2349-2359	5	33
67	Optimizing rotational atherectomy in high-risk percutaneous coronary interventions: insights from the PROTECT II study. *Catheterization and Cardiovascular Interventions*, **2014**, 83, 1057-64	2.7	29
66	Sex Differences in Outcomes Following Percutaneous Coronary Intervention According to Age. *Circulation: Cardiovascular Quality and Outcomes*, **2016**, 9, S16-25	5.8	27
65	SCAI shock classification in acute myocardial infarction: Insights from the National Cardiogenic Shock Initiative. *Catheterization and Cardiovascular Interventions*, **2020**, 96, 1137-1142	2.7	26
64	Evaluating the learning curve in the prospective Randomized Clinical Trial of hemodynamic support with Impella 2.5 versus Intra-Aortic Balloon Pump in patients undergoing high-risk percutaneous coronary intervention: a prespecified subanalysis of the PROTECT II study. *American Heart Journal*, **2014**, 167, 472-479.e5	4.9	25
63	Admission Society for Cardiovascular Angiography and Intervention shock stage stratifies post-discharge mortality risk in cardiac intensive care unit patients. *American Heart Journal*, **2020**, 219, 37-46	4.9	25
62	Risk of death and myocardial infarction in patients with peripheral arterial disease undergoing percutaneous coronary intervention (from the National Heart, Lung and Blood Institute Dynamic Registry). *American Journal of Cardiology*, **2011**, 107, 959-64	3	23
61	2015 SCAI/ACC/HFSA/STS Clinical Expert Consensus Statement on the Use of Percutaneous Mechanical Circulatory Support Devices in Cardiovascular Care (Endorsed by the American Heart Association, the Cardiological Society of India, and Sociedad Latino Americana de Cardiologia Intervencionista; Affirmation of Value by the Canadian Association of Interventional Cardiology-Association Canadienne de Cardiologie d'Intervention). *Journal of the American College of Cardiology*, **2015**, 65, 2140-59	2.7	20
60	Contemporary incidence and predictors of major adverse cardiac events after saphenous vein graft intervention with embolic protection (an AMEthyst trial substudy). *American Journal of Cardiology*, **2010**, 105, 1060-4	3	16
59	Evaluation and Management of Concomitant Hypertrophic Obstructive Cardiomyopathy and Valvular Aortic Stenosis. *Current Treatment Options in Cardiovascular Medicine*, **2016**, 18, 17	2.1	11

58	Current status and future perspectives on alcohol septal ablation for hypertrophic obstructive cardiomyopathy. *Current Cardiology Reports*, **2014**, 16, 478	4.2	10
57	SCAI SHOCK Stage Classification Expert Consensus Update: A Review and Incorporation of Validation Studies: This statement was endorsed by the American College of Cardiology (ACC), American College of Emergency Physicians (ACEP), American Heart Association (AHA), European	15.1	10
56	2015 SCAI/ACC/HFSA/STS Clinical Expert Consensus Statement on the Use of Percutaneous Mechanical Circulatory Support Devices in Cardiovascular Care (Endorsed by the American Heart Association, the Cardiological Society of India, and Sociedad Latino Americana de Cardiologí	2.7	8
55	Intervencionista; Affirmation of Value by the Canadian Association of Interventional Outcome of percutaneous coronary intervention in unstable angina pectoris versus stable angina pectoris in two different time periods. *American Journal of Cardiology*, **2006**, 98, 447-52	3	8
54	Executive Summary of the SCAI/HFSA Clinical Expert Consensus Document on the Use of Invasive Hemodynamics for the Diagnosis and Management of Cardiovascular Disease. *Journal of Cardiac Failure*, **2017**, 23, 487-491	3.3	7
53	Meta-analysis of clopidogrel pretreatment in acute coronary syndrome patients undergoing invasive strategy. *International Journal of Cardiology*, **2017**, 229, 82-89	3.2	7
52	Defining Shock and Preshock for Mortality Risk Stratification in Cardiac Intensive Care Unit Patients. *Circulation: Heart Failure*, **2021**, 14, e007678	7.6	7
51	Novel Pharmacotherapy in Hypertrophic Cardiomyopathy. *Cardiology in Review*, **2018**, 26, 239-244	3.2	6
50	Usefulness of noncoronary vascular disease in predicting adverse events in the year following percutaneous coronary intervention. *American Journal of Cardiology*, **2005**, 95, 575-80	3	5
49	Left Ventricular Assist Device Implantation in Hypertrophic and Restrictive Cardiomyopathy: A Systematic Review. *ASAIO Journal*, **2021**, 67, 239-244	3.6	5
48	Novel intracoronary steerable support catheter for complex coronary intervention. *Journal of Invasive Cardiology*, **2006**, 18, 80-1	0.7	5
47	Trends in the Use of Short-Term Mechanical Circulatory Support in the United States An Analysis of the 2012 2015 National Inpatient Sample. *Structural Heart*, **2019**, 3, 499-506	0.6	4
46	Effect of gender and race on outcomes in dialysis-dependent patients undergoing percutaneous coronary intervention. *American Journal of Cardiology*, **2011**, 107, 1319-23	3	4
45	SCAI expert consensus update on best practices in the cardiac catheterization laboratory: This statement was endorsed by the American College of Cardiology (ACC), the American Heart Association (AHA), and the Heart Rhythm Society (HRS) in April 2021. *Catheterization and*	2.7	4
44	Study design and rationale of VALOR-HCM: evaluation of mavacamten in adults with symptomatic obstructive hypertrophic cardiomyopathy who are eligible for septal reduction therapy. *American Heart Journal*, **2021**, 239, 80-89	4.9	4
43	Executive summary of the SCAI/HFSA clinical expert consensus document on the use of invasive hemodynamics for the diagnosis and management of cardiovascular disease. *Catheterization and Cardiovascular Interventions*, **2017**, 89, 1294-1299	2.7	3
42	Percutaneous Mitral Valve Repair versus Optimal Medical Therapy in Patients with Functional Mitral Regurgitation: A Systematic Review and Meta-Analysis. *Journal of Interventional Cardiology*, **2019**, 2019, 2753146	1.8	3
41	Hemodynamic Support Devices for Complex Percutaneous Coronary Intervention. *Interventional Cardiology Clinics*, **2016**, 5, 187-200	1.4	3

40	"Should SCAI update its position on the role of Public Reporting?". *Catheterization and Cardiovascular Interventions*, **2019**, 93, 448-450	2.7	3
39	Long-Term Outcomes of Drug-Eluting Stents Versus Bare-Metal Stents in End-Stage Renal Disease Patients on Dialysis: A Systematic Review and Meta-Analysis. *Cardiology in Review*, **2018**, 26, 277-286	3.2	3
38	Unprotected left main "kissing" stent implantation with a percutaneous ventricular assist device. *Journal of Invasive Cardiology*, **2004**, 16, 683-4	0.7	3
37	SCAI SHOCK Stage Classification Expert Consensus Update: A Review and Incorporation of Validation Studies **2022**, 1, 100008		2
36	Historical Perspectives in the Evolution of Hypertrophic Cardiomyopathy. *Cardiology Clinics*, **2019**, 37, 1-10	2.5	2
35	SCAI 2018 Think Tank Proceedings: "What should the role of the surgeon be in TAVR, both as a co-operator and in-patient evaluation for TAVR?. *Catheterization and Cardiovascular Interventions*, **2019**, 93, 178-179	2.7	2
34	Acute myocardial infarction in the young with diabetes mellitus- national inpatient sample study with sex-based difference in outcomes. *International Journal of Cardiology*, **2021**, 326, 35-41	3.2	2
33	A haemodynamic conundrum: a case report of a patient with concurrent pulmonary arterial hypertension and hypertrophic obstructive cardiomyopathy. *European Heart Journal - Case Reports*, **2021**, 5, ytab354	0.9	2
32	Alcohol septal ablation for failed surgical myectomy. *Journal of Invasive Cardiology*, **2005**, 17, 569-71	0.7	2
31	The declining relevance of age in the treatment of atrial septal defects. *Journal of Invasive Cardiology*, **2008**, 20, 177-8	0.7	2
30	Three years since the FDA advisory panel on drug-eluting stents: what have we learned about off-label use and stent thrombosis?. *Journal of Invasive Cardiology*, **2010**, 22, 20-1	0.7	2
29	"How can SCAI and industry partners increase adherence and educate interventionalists on optimal medical therapy?". *Catheterization and Cardiovascular Interventions*, **2019**, 93, 305-308	2.7	1
28	Interventional therapies for relief of obstruction in hypertrophic cardiomyopathy: discussion and proposed clinical algorithm. *Hospital Practice (1995)*, **2018**, 46, 58-63	2.2	1
27	Cardiac implantable electronic device placement following alcohol septal ablation for hypertrophic cardiomyopathy in the United States. *Journal of Cardiovascular Electrophysiology*, **2020**, 31, 2712-2719	2.7	1
26	Readmission following urgent transcatheter aortic valve implantation versus urgent balloon aortic valvuloplasty in patients with decompensated heart failure or cardiogenic shock. *Catheterization and Cardiovascular Interventions*, **2021**, 98, 607-612	2.7	1
25	Sex Differences in the Outcomes of Septal Reduction Therapies for Obstructive Hypertrophic Cardiomyopathy. *JACC: Cardiovascular Interventions*, **2021**, 14, 930-932	5	1
24	Investing in our future: Update on the SCAI Emerging Leader Mentorship (ELM) Program. *Catheterization and Cardiovascular Interventions*, **2016**, 88, 674-677	2.7	1
23	Here comes the sun: physician relationships with industry and the Sunshine Act. *Journal of Invasive Cardiology*, **2014**, 26, 228	0.7	1

22	Impact of intraprocedural thrombotic events on short- and long-term outcomes following percutaneous coronary intervention. Evidence from a meta-analysis. *International Journal of Cardiology*, **2016**, 202, 469-76	3.2	0
21	Indications for and Individualization of Septal Reduction Therapy **2015**, 207-222		0
20	Utilization Rates of Diagnostic and Therapeutic Vascular Procedures Among Patients Undergoing Lower Extremity Amputations in a Rural Community Hospital: A Clinicopathological Correlation. *Vascular and Endovascular Surgery*, **2021**, 55, 325-331	1.4	0
19	Characteristics and hospital outcomes of coronary atherectomy within the United States: a multivariate and propensity-score matched analysis. *Expert Review of Cardiovascular Therapy*, **2021**, 19, 865-870	2.5	0
18	Impact of Pulmonary Hypertension on In-Hospital Outcomes and 30-Day Readmissions Following Percutaneous Coronary Interventions. *Mayo Clinic Proceedings*, **2021**, 96, 2058-2066	6.4	0
17	Myosin Modulation in Hypertrophic Cardiomyopathy and Systolic Heart Failure: Getting Inside the Engine. *Circulation*, **2021**, 144, 759-762	16.7	0
16	Social Media as a Tool to Advance Women in Cardiology: Paving the Way for Gender Equality and Diversity.. *CJC Open*, **2021**, 3, S130-S136	2	0
15	Prevalence of comorbidities and symptoms stratified by severity of illness amongst adult patients with COVID-19: a systematic review.. *Archives of Medical Sciences Atherosclerotic Diseases*, **2022**, 7, e5-e23	9.9	0
14	How to assess the severity of heart failure?. *Current Opinion in Critical Care*, **2020**, 26, 386-391	3.5	
13	Interventional therapies for heart failure in the elderly. *Clinics in Geriatric Medicine*, **2007**, 23, 155-78	3.8	
12	Interventional therapies for heart failure in the elderly. *Heart Failure Clinics*, **2007**, 3, 485-500	3.3	
11	Longitudinal Case Based Presentations in HCM **2015**, 287-321		
10	Role of Advanced Testing: Invasive Hemodynamics, Endomyocardial Biopsy, and Cardiopulmonary Exercise Testing. *Cardiology Clinics*, **2019**, 37, 73-82	2.5	
9	Indications for and Individualization of Septal Reduction Therapy **2019**, 305-323		
8	Longitudinal Case-Based Presentations in HCM **2019**, 429-468		
7	Pharmacological and non-pharmacological treatment of obstructive hypertrophic cardiomyopathy. *Expert Review of Cardiovascular Therapy*, **2018**, 16, 21-26	2.5	
6	Rethinking the selection criteria for alcohol septal ablation - is it time to push the envelope?. *Journal of Invasive Cardiology*, **2010**, 22, 592-3	0.7	
5	Protecting the doctor-patient relationship. *Journal of Invasive Cardiology*, **2012**, 24, 3 p following E158	0.7	

4	Cardiac arrest in spontaneous subarachnoid hemorrhage and associated outcomes.. *Neurosurgical Focus*, **2022**, 52, E6	4.2
3	A Comparison of In-Hospital Outcomes Between the Use of Impella and IABP in Acute Myocardial Infarction Cardiogenic Shock Undergoing Percutaneous Coronary Intervention.. *Journal of Invasive Cardiology*, **2022**, 34, E98-E103	0.7
2	Meta-Analysis of Brief Dual-Antiplatelet Therapy Duration After Percutaneous Coronary Intervention.. *American Journal of Cardiology*, **2022**,	3
1	Strength training and cardiovascular health: A meta-analysis.. *Progress in Cardiovascular Diseases*, **2022**,	8.5